A Parallel-arm, Double-blind, Randomized, Placebo-controlled, Dose-ranging Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of AV7909 in Healthy Adults
| Registry | NCT01263691 |
|---|
| Status | Completed |
|---|
| Phase | Phase 1 |
|---|
| Study type | Interventional; randomized, parallel, masking: triple, prevention |
|---|
| Enrollment | 105 (Actual) |
|---|
| Sponsor | Emergent BioSolutions (Industry); collaborators: National Institute of Allergy and Infectious Diseases (NIAID), Department of Health and Human Services |
|---|
| Conditions | Bacillus Anthracis (Anthrax) Infection |
|---|
| Interventions | BioThrax, AV7909 Formulation 1, AV7909 Formulation 2, AV7909 Formulation 3, AV7909 Formulation 4, Control (Biological, drug) |
|---|
| Dates | start 2010-12-01, primary completion 2012-05-01, completion 2012-06-01, first posted 2010-12-21, last updated 2024-03-18 |
|---|
| Locations | 3 sites in United States |
|---|
Related Papers Related Patents Related Grants Related Experts
All trials for Bacillus Anthracis (Anthrax) Infection All trials of BioThrax All trials of AV7909 Formulation 1
-Summary
The purpose of this Phase 1 clinical trial is to evaluate the safety, tolerability, and immunogenicity of AV7909 anthrax vaccine in healthy adults. In this study, healthy male and female subjects between 18 and 50 years of age will receive vaccinations via the intramuscular (IM) route at Days 0 and 14. Safety and tolerability will be evaluated via laboratory tests, physical examinations, vital signs, adverse events (AEs), concomitant medications, and local and systemic signs and symptoms of reactogenicity.
Expand all sections · Collapse all
+Detailed description
AV7909 is a new vaccine which is a combination of BioThrax (also called anthrax vaccine, adsorbed or AVA), a FDA-licensed vaccine, and CPG 7909. CPG 7909 is a synthetic short DNA sequence that has been shown to be an effective vaccine adjuvant, and one which increases the speed and the degree of the immune response to Protective Antigen (PA), the major vaccine antigen. In the current study, the safety, tolerability, and antibody response to PA will be studied for four different combinations of AVA and CPG 7909, and compared to both AVA and a saline placebo. All formulations of AV7909 have the same or less AVA than the licensed AVA vaccine and all have less CPG 7909 per dose than the formulation used in the first Phase I volunteer study of CPG 7909 combined with AVA.
+Arms and interventions
| Arm | Type | Interventions | Description |
|---|
| BioThrax | Active comparator | Biological: BioThrax | BioThrax, 0.5 mL AVA per dose |
| AV7909 Formulation 1 | Experimental | Biological: AV7909 Formulation 1 | 0.5 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose |
| AV7909 Formulation 2 | Experimental | Biological: AV7909 Formulation 2 | 0.5 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose |
| AV7909 Formulation 3 | Experimental | Biological: AV7909 Formulation 3 | 0.25 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose |
| AV7909 Formulation 4 | Experimental | Biological: AV7909 Formulation 4 | 0.25 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose |
| Control | Placebo comparator | Drug: Control | Saline control |
- BioThrax (Biological), also known as Anthrax Vaccine Adsorbed (AVA): BioThrax
- AV7909 Formulation 1 (Biological): AV7909 Formulation 1
- AV7909 Formulation 2 (Biological): AV7909 Formulation 2
- AV7909 Formulation 3 (Biological): AV7909 Formulation 3
- AV7909 Formulation 4 (Biological): AV7909 Formulation 4
- Control (Drug): Saline control
+Outcome measures
Primary outcomes
- Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Vaccination (Day 0) [Days 0-6]: Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the first injection (Day 0).
All local reactions collected by subjects on diary cards were recorded as adverse events.
Severity of ISR was assessed using a grading scale based on FDA Guidance "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."
Swelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:
* Grade 0: none
* Grade 1: <3 cm
* Grade 2: 3 to 10 cm
* Grade 3: >10 cm
For all other ISRs, the following scale was used:
* Grade 0: not present
* Grade 1: present with no limitation of activity
* Grade 2: interfering with daily activities or requiring non-narcotic treatment
* Grade 3: preventing normal daily activities or requiring narcotic analgesia
- Percentage of Subjects With Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Vaccination (Day 0) [Days 0-6]: Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the first injection (Day 0).
All local reactions collected by subjects on diary cards were recorded as adverse events.
Severity of ISR was assessed using a grading scale based on FDA Guidance "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."
Swelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:
* Grade 0: none
* Grade 1: <3 cm
* Grade 2: 3 to 10 cm
* Grade 3: >10 cm
For all other ISRs, the following scale was used:
* Grade 0: not present
* Grade 1: present with no limitation of activity
* Grade 2: interfering with daily activities or requiring non-narcotic treatment
* Grade 3: preventing normal daily activities or requiring narcotic analgesia
- Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Vaccination (Day 14) [Days 14-20]: Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the second injection (Day 14).
All local reactions collected by subjects on diary cards were recorded as adverse events.
Severity of ISR was assessed using a grading scale based on FDA Guidance "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."
Swelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:
* Grade 0: none
* Grade 1: <3 cm
* Grade 2: 3 to 10 cm
* Grade 3: >10 cm
For all other ISRs, the following scale was used:
* Grade 0: not present
* Grade 1: present with no limitation of activity
* Grade 2: interfering with daily activities or requiring non-narcotic treatment
* Grade 3: preventing normal daily activities or requiring narcotic analgesia
- Percentage of Subjects With Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Vaccination (Day 14) [Days 14-20]: Subjects recorded solicited injection site reactions (ISRs) (redness, swelling, tenderness, pain, itching, arm motion limitation) on diary cards for 7 days following the second injection (Day 14).
All local reactions collected by subjects on diary cards were recorded as adverse events.
Severity of ISR was assessed using a grading scale based on FDA Guidance "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."
Swelling/edema and redness/erythema were graded by the greater of two perpendicular measurements of diameter rated as follows:
* Grade 0: none
* Grade 1: <3 cm
* Grade 2: 3 to 10 cm
* Grade 3: >10 cm
For all other ISRs, the following scale was used:
* Grade 0: not present
* Grade 1: present with no limitation of activity
* Grade 2: interfering with daily activities or requiring non-narcotic treatment
* Grade 3: preventing normal daily activities or requiring narcotic analgesia
- Incidence of Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Injection (Day 0) [Days 0-6]: Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.
Severity of systemic reactions was assessed using a grading scale based on FDA Guidance titled "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."
Toxicity grades for fever were derived from body temperature using the following scale:
* Grade 0: <100°F
* Grade 1: 100.0 - 101.5°F
* Grade 2: 101.6 - 102.9°F ;
* Grade 3: 103.0 - 105.0°F
For all other systemic reactions, the following scale was used:
* Grade 0: not present
* Grade 1: present with no limitation of activity
* Grade 2: interfering with daily activities or requiring non-narcotic treatment
* Grade 3: preventing normal daily activities or requiring narcotic analgesia
- Percentage of Subjects With Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Injection (Day 0) [Days 0-6]: Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.
Severity of systemic reactions was assessed using a grading scale based on FDA Guidance titled "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."
Toxicity grades for fever were derived from body temperature using the following scale:
* Grade 0: <100°F
* Grade 1: 100.0 - 101.5°F
* Grade 2: 101.6 - 102.9°F ;
* Grade 3: 103.0 - 105.0°F
For all other systemic reactions, the following scale was used:
* Grade 0: not present
* Grade 1: present with no limitation of activity
* Grade 2: interfering with daily activities or requiring non-narcotic treatment
* Grade 3: preventing normal daily activities or requiring narcotic analgesia
- Incidence of Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Injection (Day 14) [Days 14-20]: Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.
Severity of systemic reactions was assessed using a grading scale based on FDA Guidance titled "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."
Toxicity grades for fever were derived from body temperature using the following scale:
* Grade 0: <100°F
* Grade 1: 100.0 - 101.5°F
* Grade 2: 101.6 - 102.9°F ;
* Grade 3: 103.0 - 105.0°F
For all other systemic reactions, the following scale was used:
* Grade 0: not present
* Grade 1: present with no limitation of activity
* Grade 2: interfering with daily activities or requiring non-narcotic treatment
* Grade 3: preventing normal daily activities or requiring narcotic analgesia
- Percentage of Subjects With Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Injection (Day 14) [Days 14-20]: Subjects recorded solicited systemic reactions (fever, fatigue, muscle aching, headache, nausea/GI upset) on diary cards for 7 days following each of two injections (Days 0 and 14) All systemic reactions collected by subjects on diary cards were recorded as adverse events.
Severity of systemic reactions was assessed using a grading scale based on FDA Guidance titled "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials."
Toxicity grades for fever were derived from body temperature using the following scale:
* Grade 0: <100°F
* Grade 1: 100.0 - 101.5°F
* Grade 2: 101.6 - 102.9°F ;
* Grade 3: 103.0 - 105.0°F
For all other systemic reactions, the following scale was used:
* Grade 0: not present
* Grade 1: present with no limitation of activity
* Grade 2: interfering with daily activities or requiring non-narcotic treatment
* Grade 3: preventing normal daily activities or requiring narcotic analgesia
- Incidence of Hematology, Serum Chemistry, and Urinalysis Abnormalities Reported as Adverse Events [Days 0-56]: Hematology test included hemoglobin, hematocrit, white blood cell count, absolute lymphocyte count, absolute neutrophil count, absolute eosinophil count, and platelet count. Serum chemistry test included albumin, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine, glucose, calcium, potassium, alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase. Urinalysis included appearance, color, pH, specific gravity, ketones, protein, glucose, bilirubin, nitrite, urobilinogen, and occult blood.
Hematology tests were done on Days 0, 1, 2, 7, 28, and 56. Serum chemistry tests and urinalysis were done on Days 0, 7, 28, and 56.
- Percentage of Subjects With Hematology, Serum Chemistry, and Urinalysis Abnormalities Reported as Adverse Events [Days 0-56]: Hematology test included hemoglobin, hematocrit, white blood cell count, absolute lymphocyte count, absolute neutrophil count, absolute eosinophil count, and platelet count. Serum chemistry test included albumin, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine, glucose, calcium, potassium, alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase. Urinalysis included appearance, color, pH, specific gravity, ketones, protein, glucose, bilirubin, nitrite, urobilinogen, and occult blood.
Hematology tests were done on Days 0, 1, 2, 7, 28, and 56. Serum chemistry tests and urinalysis were done on Days 0, 7, 28, and 56.
Secondary outcomes
- Peak TNA NF50 GMT for All Subjects in the Immunogenicity Population and by Gender After IM Administration of Investigational Product on Days 0 and 14. [Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84.]: Toxin neutralizing antibody (TNA) levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50). TNA NF50 is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum. Values below the lower limit of quantitation (LLOQ) of the assay (ED50 of 33) were replaced with one-half the LLOQ (ED50 of 16.5) for calculation of geometric mean titer (GMT) and statistical analysis. GMT is based on log transformation.
- Median Time to Peak TNA NF50 GMT for All Subjects in the Immunogenicity Population and by Gender After IM Administration of Investigational Product on Days 0 and 14. [Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84.]: Toxin neutralizing antibody (TNA) levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50). TNA NF50 is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum. Values below the LLOQ of the assay (ED50 of 33) were replaced with one-half the LLOQ (ED50 of 16.5) for calculation of geometric mean titer (GMT) and statistical analysis. GMT is based on log transformation.
- TNA NF50 GMTs Across Study Days After IM Administration of Investigational Product on Days 0 and 14. [Day 0 (pre-dose), 7, 14 (pre-dose), 21, 28, 35, 42, 56, 70, and 84.]: Toxin neutralizing antibody (TNA) levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50). TNA NF50 is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum. Values below the LLOQ of the assay (ED50 of 33) were replaced with one-half the LLOQ (ED50 of 16.5) for calculation of geometric mean titer (GMT) and statistical analysis. GMT is based on log transformation.
+Eligibility
Sex: All, ages: 18 Years to 50 Years, accepts healthy volunteers
Inclusion Criteria:
* Be between 18 and 50 years of age, inclusive, at the time of enrollment.
* Be in good health as determined by the investigator from medical history and a physical examination.
* If a pre-menopausal female, must be using acceptable methods of birth control.
* Have all hematology and chemistry parameters (measured at Screening) within the laboratory's normal range.
* Have negative values for the following tests at Screening: Hepatitis C antibody, anti-Human Immunodeficiency Virus (Anti-HIV-1/-2/-O), and anti-Hepatitis B Core Antigen (Anti-HBc).
* Be willing and capable of complying with all aspects of the protocol through completion of the required visits.
* Have not donated blood in the preceding 8 weeks and are willing to not donate blood or plasma within 56 days after dosing.
* Have adequate venous access for repeat phlebotomies.
* Have read, understood and signed an informed consent form.
Exclusion Criteria:
Key Exclusion Criteria:
* A known anaphylactic response, severe systematic response, or serious hypersensitivity reaction to a prior immunization.
* Prior immunization with anthrax vaccine, recombinant Protective Antigen (rPA) vaccine, or known exposure to anthrax organisms.
* Have previously served in the military or plans to enlist in the military from Screening through Day 84.
* Have participated in anthrax therapeutic or vaccine trials (monoclonal anti-protective antigen (PA) or anthrax immune globulins or anthrax vaccines).
* Participation in any investigational clinical trial within 30 days preceding the Screening visit or planning to participate in a clinical trial requiring dosing through the Day 194 visit.
* A history of drug or alcohol abuse within 12 months prior to Screening, or a positive result on a urine drug screen for amphetamines, barbiturates, benzodiazepines, cocaine, marijuana, methylenedioxymethamphetamine opiates, oxycodone, phencyclidine, propoxyphene, or tricyclic antidepressants.
* Blood pressure greater than 145 millimeters of mercury (mmHg) systolic or 90 mmHg diastolic.
* Past history of significant autoimmune disease such as rheumatoid arthritis, lupus erythematous, psoriasis, glomerulonephritis, or autoimmune thyroiditis.
* A medical condition that, in the opinion of the Principal Investigator (PI), could adversely impact the subject's participation, safety, or conduct of the study.
+Posted results
Participant flow
| Milestone | BioThrax | AV7909 Formulation 1 | AV7909 Formulation 2 | AV7909 Formulation 3 | AV7909 Formulation 4 | Saline |
|---|
| Started | 18 | 18 | 17 | 19 | 18 | 15 |
| Completed | 15 | 18 | 16 | 18 | 18 | 15 |
| Not completed | 3 | 0 | 1 | 1 | 0 | 0 |
Outcome results
- Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Vaccination (Day 0) (Primary), Number, Participants: BioThrax 11; AV7909 Formulation 1 17; AV7909 Formulation 2 13; AV7909 Formulation 3 12; AV7909 Formulation 4 16; Saline 1
- Peak TNA NF50 GMT for All Subjects in the Immunogenicity Population and by Gender After IM Administration of Investigational Product on Days 0 and 14. (Secondary), Geometric mean, geometric mean titer: BioThrax 0.15 (0.07 to 0.30); AV7909 Formulation 1 3.40 (2.33 to 4.94); AV7909 Formulation 2 4.02 (2.46 to 6.57); AV7909 Formulation 3 2.81 (1.50 to 5.26); AV7909 Formulation 4 1.93 (0.85 to 4.43); Saline 0.04 (0.02 to 0.08); Male BioThrax 0.19 (0.06 to 0.62); Male AV7909 Formulation 1 3.44 (1.84 to 6.43); Male AV7909 Formulation 2 4.19 (2.19 to 7.98); Male AV7909 Formulation 3 2.99 (1.32 to 6.78); Male AV7909 Formulation 4 2.45 (0.54 to 11.12); Male Saline 0.03 (NA to NA); Female BioThrax 0.11 (0.04 to 0.36); Female AV7909 Formulation 1 3.35 (1.91 to 5.88); Female AV7909 Formulation 2 3.87 (1.54 to 9.71); Female AV7909 Formulation 3 2.68 (0.92 to 7.80); Female AV7909 Formulation 4 1.53 (0.53 to 4.39); Female Saline 0.06 (0.01 to 0.21)
- Percentage of Subjects With Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Vaccination (Day 0) (Primary), Number, Percentage of Participants: BioThrax 61.1; AV7909 Formulation 1 94.4; AV7909 Formulation 2 76.5; AV7909 Formulation 3 63.2; AV7909 Formulation 4 88.9; Saline 6.7
- Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Vaccination (Day 14) (Primary), Number, Participants: BioThrax 11; AV7909 Formulation 1 16; AV7909 Formulation 2 12; AV7909 Formulation 3 11; AV7909 Formulation 4 13; Saline 0
- Percentage of Subjects With Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Vaccination (Day 14) (Primary), Number, Percentage of Participants: BioThrax 61.1; AV7909 Formulation 1 88.9; AV7909 Formulation 2 70.6; AV7909 Formulation 3 57.9; AV7909 Formulation 4 72.2; Saline 0
- Incidence of Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Injection (Day 0) (Primary), Number, Participants: BioThrax 10; AV7909 Formulation 1 12; AV7909 Formulation 2 7; AV7909 Formulation 3 3; AV7909 Formulation 4 7; Saline 5
- Percentage of Subjects With Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the First Injection (Day 0) (Primary), Number, percentage of participants: BioThrax 55.6; AV7909 Formulation 1 66.7; AV7909 Formulation 2 41.2; AV7909 Formulation 3 15.8; AV7909 Formulation 4 38.9; Saline 33.3
- Incidence of Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Injection (Day 14) (Primary), Number, participants: BioThrax 7; AV7909 Formulation 1 14; AV7909 Formulation 2 7; AV7909 Formulation 3 4; AV7909 Formulation 4 9; Saline 2
- Percentage of Subjects With Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild, Moderate or Severe) Following the Second Injection (Day 14) (Primary), Number, percentage of participants: BioThrax 38.9; AV7909 Formulation 1 77.8; AV7909 Formulation 2 41.2; AV7909 Formulation 3 21.1; AV7909 Formulation 4 50.0; Saline 13.3
- Incidence of Hematology, Serum Chemistry, and Urinalysis Abnormalities Reported as Adverse Events (Primary), Number, participants: BioThrax 0; AV7909 Formulation 1 0; AV7909 Formulation 2 1; AV7909 Formulation 3 0; AV7909 Formulation 4 1; Saline 1
- Percentage of Subjects With Hematology, Serum Chemistry, and Urinalysis Abnormalities Reported as Adverse Events (Primary), Number, percentage of participants: BioThrax 0; AV7909 Formulation 1 0; AV7909 Formulation 2 5.9; AV7909 Formulation 3 0; AV7909 Formulation 4 5.6; Saline 6.7
- Median Time to Peak TNA NF50 GMT for All Subjects in the Immunogenicity Population and by Gender After IM Administration of Investigational Product on Days 0 and 14. (Secondary), Median, days: BioThrax 28.0 (7 to 42); AV7909 Formulation 1 29.0 (21 to 42); AV7909 Formulation 2 28.0 (22 to 35); AV7909 Formulation 3 28.5 (27 to 42); AV7909 Formulation 4 29.0 (7 to 42); Saline 7.0 (6 to 70); Male BioThrax 28.0 (7 to 35); Male AV7909 Formulation 1 28.0 (21 to 42); Male AV7909 Formulation 2 28.0 (22 to 35); Male AV7909 Formulation 3 28.0 (28 to 39); Male AV7909 Formulation 4 28.0 (7 to 35); Male Saline 7.0 (7 to 8); Female BioThrax 18.5 (7 to 42); Female AV7909 Formulation 1 32.0 (28 to 36); Female AV7909 Formulation 2 28.0 (22 to 30); Female AV7909 Formulation 3 29.0 (27 to 42); Female AV7909 Formulation 4 35.0 (21 to 42); Female Saline 7.0 (6 to 70)
- TNA NF50 GMTs Across Study Days After IM Administration of Investigational Product on Days 0 and 14. (Secondary), Geometric mean, geometric mean titer: BioThrax 0.03 (NA to NA); AV7909 Formulation 1 0.03 (NA to NA); AV7909 Formulation 2 0.03 (NA to NA); AV7909 Formulation 3 0.03 (NA to NA); AV7909 Formulation 4 0.03 (NA to NA); Saline 0.03 (NA to NA)
Adverse events
Time frame: Serious adverse event data were collected at study visits from Day 0 to Day 84 and during safety follow-up telephone calls at 6 and 12 months.
| Arm | Deaths | Serious adverse events | Other adverse events |
|---|
| BioThrax | 0 | 0/18 (0.0%) | 16/18 (88.9%) |
| AV7909 Formulation 1 | 0 | 1/18 (5.6%) | 18/18 (100.0%) |
| AV7909 Formulation 2 | 0 | 1/17 (5.9%) | 14/17 (82.4%) |
| AV7909 Formulation 3 | 0 | 0/19 (0.0%) | 14/19 (73.7%) |
| AV7909 Formulation 4 | 0 | 0/18 (0.0%) | 18/18 (100.0%) |
| Saline | 0 | 1/15 (6.7%) | 9/15 (60.0%) |
Serious adverse events by term
| Term | Organ system | BioThrax | AV7909 Formulation 1 | AV7909 Formulation 2 | AV7909 Formulation 3 | AV7909 Formulation 4 | Saline |
|---|
| Elevated hepatic enzymes | Investigations | 0/18 | 0/18 | 0/17 | 0/19 | 0/18 | 1/15 |
| Melanocytic Naevus | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/18 | 0/18 | 1/17 | 0/19 | 0/18 | 0/15 |
| Death | Social circumstances | 0/18 | 1/18 | 0/17 | 0/19 | 0/18 | 0/15 |
Other adverse events by term
| Term | Organ system | BioThrax | AV7909 Formulation 1 | AV7909 Formulation 2 | AV7909 Formulation 3 | AV7909 Formulation 4 | Saline |
|---|
| Fatigue | General disorders | 8/18 | 13/18 | 6/17 | 4/19 | 9/18 | 3/15 |
| Headache | Nervous system disorders | 6/18 | 11/18 | 5/17 | 5/19 | 10/18 | 2/15 |
| Injection Site Reaction | General disorders | 15/18 | 18/18 | 14/17 | 14/19 | 16/18 | 2/15 |
| Lymphocyte Count Decreased | Investigations | 0/18 | 6/18 | 3/17 | 1/19 | 4/18 | 0/15 |
| Myalgia | Musculoskeletal and connective tissue disorders | 8/18 | 10/18 | 4/17 | 2/19 | 10/18 | 2/15 |
| Nausea | Gastrointestinal disorders | 2/18 | 6/18 | 3/17 | 2/19 | 4/18 | 1/15 |
| Pyrexia | General disorders | 1/18 | 2/18 | 3/17 | 1/19 | 3/18 | 2/15 |
| Upper Respiratory Tract Infection | Infections and infestations | 5/18 | 1/18 | 3/17 | 1/19 | 2/18 | 2/15 |
| White Blood Cell Count Decreased | Investigations | 2/18 | 5/18 | 4/17 | 0/19 | 2/18 | 1/15 |
| Rotator Cuff Syndrome | Musculoskeletal and connective tissue disorders | 0/18 | 1/18 | 0/17 | 0/19 | 0/18 | 0/15 |
| Tendonitis | Musculoskeletal and connective tissue disorders | 0/18 | 1/18 | 0/17 | 0/19 | 0/18 | 0/15 |
| Facial Bones Fracture | Injury, poisoning and procedural complications | 0/18 | 1/18 | 0/17 | 0/19 | 1/18 | 0/15 |
| Blepharospasm | Eye disorders | 0/18 | 0/18 | 0/17 | 0/19 | 1/18 | 0/15 |
| Concussion | Injury, poisoning and procedural complications | 0/18 | 0/18 | 0/17 | 0/19 | 1/18 | 0/15 |
| Jaw Fracture | Injury, poisoning and procedural complications | 0/18 | 0/18 | 0/17 | 0/19 | 1/18 | 0/15 |
| Laceration | Injury, poisoning and procedural complications | 0/18 | 0/18 | 0/17 | 0/19 | 1/18 | 0/15 |
| Sternal Fracture | Injury, poisoning and procedural complications | 0/18 | 0/18 | 0/17 | 0/19 | 1/18 | 0/15 |
| Traumatic Lung Injury | Injury, poisoning and procedural complications | 0/18 | 0/18 | 0/17 | 0/19 | 1/18 | 0/15 |
| Alanine aminotransferase increased | Investigations | 0/18 | 0/18 | 1/17 | 0/19 | 1/18 | 1/15 |
| Aspartate aminotransferase increased | Investigations | 0/18 | 0/18 | 0/17 | 0/19 | 2/18 | 0/15 |
| Blood creatine increased | Investigations | 0/18 | 0/18 | 1/17 | 0/19 | 0/18 | 0/15 |
| Blood lactate dehydrogenase increased | Investigations | 0/18 | 0/18 | 0/17 | 0/19 | 0/18 | 1/15 |
| Blood urea increased | Investigations | 0/18 | 1/18 | 0/17 | 0/19 | 0/18 | 0/15 |
| Hepatic enzyme increased | Investigations | 0/18 | 0/18 | 0/17 | 0/19 | 0/18 | 1/15 |
| Hyperkalemia | Investigations | 0/18 | 1/18 | 0/17 | 0/19 | 0/18 | 0/15 |
| Hypoglycemia | Investigations | 0/18 | 1/18 | 0/17 | 2/19 | 0/18 | 0/15 |
| Hypokalemia | Investigations | 0/18 | 0/18 | 1/17 | 1/19 | 0/18 | 0/15 |
| Hypomagnesemia | Investigations | 0/18 | 0/18 | 0/17 | 1/19 | 0/18 | 0/15 |
| Neutropenia | Investigations | 1/18 | 1/18 | 0/17 | 0/19 | 0/18 | 0/15 |
| Neutrophil count decreased | Investigations | 0/18 | 1/18 | 0/17 | 0/19 | 0/18 | 0/15 |
| Protein urine | Investigations | 0/18 | 1/18 | 0/17 | 1/19 | 1/18 | 1/15 |
| Red blood cells urine positive | Investigations | 0/18 | 0/18 | 1/17 | 0/19 | 0/18 | 0/15 |
| White blood cell count increased | Investigations | 0/18 | 1/18 | 0/17 | 0/19 | 0/18 | 0/15 |
| White blood cells urine positive | Investigations | 0/18 | 0/18 | 1/17 | 0/19 | 0/18 | 0/15 |
+Locations (3)
| Facility | City | Country | Status |
|---|
| Miami Research Associates | Miami, Florida | United States | |
| North Carolina Clinical Research | Raleigh, North Carolina | United States | |
| Jean Brown Research | Salt Lake City, Utah | United States | |
+Publications
- Results publication: Hopkins RJ, Daczkowski NF, Kaptur PE, Muse D, Sheldon E, LaForce C, Sari S, Rudge TL, Bernton E. Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers. Vaccine. 2013 Jun 26;31(30):3051-8. doi: 10.1016/j.vaccine.2013.04.063. Epub 2013 May 10. PMID 23701746
+Investigators